Trial Profile
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bendamustine; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Seagen
- 13 Sep 2018 Status changed to discontinued as per sponsors decision based on portfolio prioritization
- 30 Oct 2017 Status changed from active, no longer recruiting to completed.
- 30 May 2017 Status changed from recruiting to active, no longer recruiting.